Congenital cytomegalovirus (CMV) In renal transplantation and in HIV infection, high-dose regimens of valacyclovir are effective in preventing CMV disease and suppressing CMV viremia
Background: The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time
Congenital CMV infection was defined as a positive result by polymerase chain reaction from urine, saliva or cerebrospinal fluid or positive CMV IgM from neonatal blood sampled within 3 weeks after birth
atic congenital cytomegalovirus infection at birth
If primary maternal CMV infection is diagnosed during pregnancy, or abnormal sonographic findings suggest congenital CMV infection, Both oral valacyclovir and CMV-specific hyperimmune globulin (CMV-HIG) have been studied to prevent fetal CMV infection (i
Cytomegalovirus (pronounced sy-toe-MEG-a-low-vy-rus), or CMV, is a common virus that infects people of all ages
demonstrated a two-thirds reduction in the rate of congenital CMV infection in women treated with oral valacyclovir of 8 g per
The major adverse effects of ganciclovir therapy include fever, rash, diarrhea, and hematologic effects (ie, neutropenia Congenital CMV transmission and disease
The objective of this study was to evaluate the long-term hearing outcomes among symptomatic CMV patients treated with VGCV
2% to 2
Prior maternal exposure to CMV does not preclude neonatal infection
Cytomegalovirus (CMV) is the most common cause of congenital infection, affecting 0